Push Admin

Fil-Am biotech CEO unveils possible 'novel treatment' vs COVID-19

Article (news)

Bettina Magsaysay, ABS-CBN News

MANILA - As experts around the world are racing to find a vaccine against the coronavirus disease 2019 (COVID-19), one Filipino scientist is taking a different approach towards treating the contagious disease.Filipino-American Rogelio &quot;Vonz&quot; Santos Jr., CEO of biotech firm Nucision, said he has developed a novel treatment called &quot;Relivir&quot; against COVID-19.Neither a vaccine nor an antibody treatment, Relivir sits somewhere in the middle. It works by delivering a &quot;programmable&quot; enzyme that &quot;cuts&quot; the RNA of the SARS-CoV-2, essentially removing the virus&#x27; ability to replicate and multiply within a host&#x27;s body, he said.When the virus can no longer replicate, it can no longer infect new cells thereby stopping its severe effects on the human body.&quot;What that means, is that we are able to directly address not just the elimination of the virus but the replication rate,&quot; Santos said.He added, &quot;The replication rate is very important to address because if we don&#x27;t address it at its source no matter how many treatments you put in the blood stream it will end up continuing to grow. You are constantly in a battle.&quot;Most scientists focus on treating COVID-19 by building immunity either through a vaccine or an antibody treatment or repurposing existing antiviral drugs.This treatment can be delivered intravenously or through inhaler. Nucision researchers believed that this could be given at any stage of the infection.In a couple of weeks, Santos said they should be able to wrap up the first batch of their testing. &quot;We will then initiate and engage in animal studies and toxicity testing. We have been working with the Philippine agencies there to prepare for human clinical trials. This is not a vaccine, this is not an antibody and it does not really rely on the immune response,&quot; he said.Santos said they had been in talks with the Inter-Agency Task Force (IATF) and other hospitals for possible clinical trials.For now, there is no specific date when the product will be available on the market. He said this would depend on regulatory approval. But Santos is encouraged that there is a priority for these kinds of projects. &quot;If all things are successful then we can look at 2021 as a potential time frame for either early release through ;compassionate use,&#x27; clinical trials and if full commercial capacity has been approved, our next challenge will be to make sure we have enough manufacturing and distribution partners,&quot; he said.

As experts around the world are racing to find a vaccine to arrest COVID-19, one Filipino scientist is taking a different approach towards treating the contagious disease.

As experts around the world are racing to find a vaccine to arrest COVID-19, one Filipino scientist is taking a different approach towards treating the contagious disease.

Fil-Am biotech CEO unveils possible 'novel treatment' vs COVID-19

News

Entertainment

Lifestyle

Sports

Metro.Style

More

Traffic

Manila

Horoscope

News

Fil-Am biotech CEO unveils possible 'novel treatment' vs COVID-19

Bettina Magsaysay,

ABS-CBN News

Published Aug 05, 2020 11:07 PM PHT

Read More:

COVID-19 Philippines update

COVID-19 treatment Nucision

COVID-19 treatment Relivir

COVID-19 treatment Rogelio Santos Jr

ABS-CBN is the leading media and entertainment company in the Philippines, offering quality content across TV, radio, digital, and film. Committed to public service and promoting Filipino values, ABS-CBN continues to inspire and connect audiences worldwide.

Corporate

Investors

Governance

International Distribution

Corporate

Governance

Investors

International Distribution

NPC Seal of Registration

Privacy Policy

AI Policy

Terms of Service

Advertise with Us

© 2025 ABS-CBN Corporation. All Rights Reserved.

NPC Seal of Registration

Privacy Policy

Terms of Service

AI Policy

Advertise with Us

© 2025 ABS-CBN Corporation. All Rights Reserved.

NPC Seal of Registration

Privacy Policy

Terms of Service

AI Policy

Advertise with Us

© 2025 ABS-CBN Corporation. All Rights Reserved.